Get to know our clinical trials
Clinical trial of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other antineoplastic treatments for the treatment of urothelial cancer.
WE ARE CONDUCTING THIS STUDY TO EVALUATE HOW WELL ENFORTUMAB VEDOTIN WORKS WHEN GIVEN AS MONOTHERAPY OR WITH PEMBROLIZUMAB TO PATIENTS WITH UROTHELIAL CANCER. WE ALSO WANT TO FIND OUT THE SIDE EFFECTS OF GIVING ENFORTUMAB VEDOTIN AS MONOTHERAPY OR WITH PEMBROLIZUMAB FOR UROTHELIAL CANCER.
- STUDY OF ENFORTUMAB VEDOTIN (ASG-22CE) AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTINEOPLASTIC TREATMENTS FOR THE TREATMENT OF UROTHELIAL CANCER. IMMUNOTHERAPY
- Code EudraCT: 2018-001527-39
- Protocol number: SGN22E-002
- Promoter: Seagen Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.